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Abstract
Objectives Serotonin is a monoamine neurotransmitter that is widely distributed
in the body and plays an important role in a variety of psychological and other body
functions such as mood, sexual desire and function, appetite, sleep, memory and
learning, temperature regulation and social behaviour. This review will assess the
use of fluoxetine, one of the most commonly used selective serotonin reuptake
inhibitors, as a model for understanding the molecular pharmacology of the sero-
toninergic system.
Key findings Seven serotonin receptor families have been discovered to date. All
serotonin receptors, except 5-HT3, are G-protein coupled, seven transmembrane
receptors that activate an intracellular second messenger cascade. The 5-HT3 recep-
tor is a ligand-gated ion channel. Furthermore, 5-HT1A receptors are known as
autoreceptors since their stimulation inhibits the release serotonin in nerve termi-
nals.A transporter protein found in the plasmamembrane of serotonergic neurones
is responsible for the reuptake of this neurotransmitter. Selective serotonin reuptake
inhibitors, such as fluoxetine, act primarily at the serotonin transporter protein and
have limited, if any, reaction with other neurotransmitter systems. Selective seroto-
nin reuptake inhibitors appear to bind with the serotonin transporter with different
rates of occupancy, duration and potency.
Summary The following review focuses on the interaction of serotonin with this
membrane transporter in the body and assesses the use of fluoxetine as a reference
drug in the understanding of this interaction.
Introduction
The selective serotonin reuptake inhibitor (SSRI) fluoxetine is
one of the most widely used drugs in its class, and it is used in
the treatment of depression, obsessive-compulsive disorder,
bulimia and panic disorder.[1] It is considered to be the refer-
ence drug for the treatment of depression. The other com-
mercially available SSRIs include citalopram, escitalopram,
fluvoxamine, paroxetine and sertraline. Despite the fact that
SSRIs have very different molecular structures, they all have
similar mechanisms of action, albeit with slightly different
pharmacokinetic properties, which may lead to small differ-
ences in some pharmacokinetic parameters such as half-life,
and differences in clinical and adverse and drug interac-
tions.[2] Fluoxetine was the first drug of its class that was
approved by the regulatory authorities in Europe and the
USA. It is well absorbed from the gastrointestinal tract and its
bioavailability is about 72%. Peak plasma concentrations are
observed after 6 to 8 h.[3] Food does not appear to affect the
systemic bioavailability of fluoxetine, although it may delay
its absorption by 1 to 2 h, which is probably not clinically
significant.[4] Fluoxetine is a chiral molecule that is commer-
cially available as a racemic mixture, i.e. a 50 : 50 mixture of
its enantiomers (R)-fluoxetine and (S)-fluoxetine.
Fluoxetine, similar to other SSRIs, has been shown to exert
its antidepressant effect by interacting with a membrane
protein. The following review focuses on the interaction of
serotonin with this membrane protein in the body and how
fluoxetine, as the reference drug in this class, interferes with
this interaction in order to carry out its pharmacological
effects. The developments with respect to the molecular
understanding of these interactions are key to the develop-
ment of more targeted drug molecules acting on this impor-
tant system. Table 1 gives an overview of the mode of action,
adverse effects and pharmacokinetic parameters of fluoxetine
and other SSRIs. Newer SSRIs have fewer adverse effects than
fluoxetine, i.e. fewer activating side effects (e.g. insomnia, agi-
tation, tremor and anxiety) and fewer gastrointestinal adverse
events (e.g. nausea, vomiting, diarrhoea, weight loss and
anorexia). These side effects had lead to non-adherence issues
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in some patients, which undermined the efficacy of fluoxet-
ine. However these side effects resolve in the majority of
patients and become significantly less frequent with contin-
ued treatment over a 6-month period.[2]
Serotonin transporter
Serotonin (5-hydroxytryptamine, 5-HT), amonoamine neu-
rotransmitter, plays an important role in many behaviours,
including sleep, appetite, memory, sexual behaviour, neu-
roendocrine function and mood. In the brain, the highest
level of serotonin is found in the dorsal and median raphe
nuclear complex.[6] Neurones in the raphe system project
beyond the raphe nucleus,most often in the lateral direction.
Numerous serotonergic neurones are also found in the
reticular region of the lower brain stem. Neurones in the
brain stem are often divided into a caudal system and a rostral
system.Nerve cells in the caudal system descend to the spinal
cord alongmanypathways and are largely involved in sensory,
motor and autonomic functioning. Serotonergic cells in the
rostral system of the brainstem largely terminate in the dorsal
andmedian raphe nuclei.
One other major serotonergic pathway in the brain is that
from the cerebellum, which terminates in the cerebellar
cortex and the cerebellar nuclei.Many serotonergic neurones
contribute to this pathway.The presence of serotonin has also
been observed in the pons, medulla, thalamus, hypothala-
mus, substantia nigra and locus coeruleus.[7] Serotonin is
synthesised from the amino acid precursor tryptophan,pack-
aged into vesicles in the presynaptic area and released into the
synapse following an action potential. Once in the synapse,
serotonin can interact with both presynaptic and post-
synaptic receptors. However, immediately after interaction
it is critically important for serotonin to be removed from
the system.
Reuptake, the process of removing neurotransmitters
from the synaptic cleft after release, determines the extent,
duration and spatial domain of receptor activation.[8] Any
neurotransmitter not removed from the synaptic cleft pre-
vents further signals from passing through. Active removal
reduces the level of neurotransmitter in the cleft faster
than diffusion, constrains the effects of released neuro-
transmitter to smaller areas and allows at least part of the
released chemical to be recycled for further use. Reuptake
is carried out by transporter proteins that bind to the
released neurotransmitter and carry it across the plasma
membrane and back into the presynaptic neurone. In the
case of serotonin, reuptake is carried out by the serotonin
transporter (SERT).
Protein structure
The serotonin transporter is a carrier of serotonin molecules
across the biological membrane.[9] Transporters undergo
conformational changes and move one or more molecules
per ‘cycle’, unlike channels, which stay open or closed, thus
allowing floods of molecules to move across bilayer mem-
branes. The serotonin transporter resembles other biogenic
amine transporters structurally and functionally, such as
norepinephrine and dopamine transporters.
The protein structure is composed of 12 transmembrane
helices with an extracellular loop between transmembrane
helices 3 and 4.[10] Both polypeptide termini are located
within the cytoplasm and six putative phosphorylation sites,
which are potential targets for protein kinase A and protein
kinase C, exist in the same compartment. The areas impor-
tant for selective serotonin affinity are localisedwithin helices
1 to 3 and helices 8 to 12. A binding site for serotonin is
believed also to be the target of selective inhibitors, such as
fluoxetine (Figure 1).
Mechanism of action
Serotonin reuptake transporters are dependent on extracel-
lular sodium (Na+) ions and extracellular chloride (Cl–)
ions. Unlike sodium ions, choride ions can be at least partly
substituted for by bicarbonate ions (HCO3–). Intracellular
potassium ions (K+) are also used in the process but can be
replaced by other ions, most notably hydrogen (H+) ions.
The driving force for the energetically unfavourable trans-
port of serotonin is the sodium ion influx down its concen-
tration gradient.[12] The Na+/K+ ATPase pump maintains the
extracellular sodium ion concentration as well as the intrac-
ellular potassium ion concentration. Na+/K+ ATPase pumps
three sodium ions out for each two potassium ions pumped
into the cell. The electrical potential produced, in addition
to creating the sodium ion concentration used by the trans-
porter protein, also leads to the loss of chloride ions from
the cell.
According to the model of serotonin transporter
function, the first step occurs when a sodium ion binds
to the carrier protein. Serotonin, in its protonated form
(5-HT+), then binds to the transporter followed by a chlo-
ride ion. Chloride ions are not required for protonated
serotonin binding to occur but are necessary for net
transport to take place. The initial complex of serotonin, a
sodium ion and a chloride ion creates a conformational
change in the transporter protein.[13] The protein, which
begins by facing the outside of the neurone, moves to an
inward position where the neurotransmitter and ions are
released into the cytoplasm of the neurone. An intracellular
potassium ion then binds to the serotonin transporter to
promote reorientation of the carrier for another transport
cycle. The unoccupied binding site becomes, once again,
exposed to the outside of the cell and the potassium ion is
released outside the cell.
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Mode of action of selective serotonin
reuptake inhibitors
The synaptic reuptake of serotonin is susceptible to drug
manipulation. By blocking the action of serotonin tranport-
ers, the amount of serotonin in the synaptic cleft increases.
SSRIs act primarily at the serotonin transporter protein and
have limited, if any, reaction with other neurotransmitter
systems. Such agents bind to the transporter protein directly
and block the reuptake process.[14] Consequently, more sero-
tonin remains in the cleft, where it is free to travel to more
distant receptors as well as to continue to react with nearby
receptors. Like the binding of substrates, antagonist binding
to serotonin transporters is also dependent on extracellular
sodium ions although ion dependency is different for each
antagonist. It is unclear whether these inhibitors bind to the
same serotonin transporter domain as serotonin does or
operate throughmore indirect mechanisms.
The binding of SSRIs to serotonin transporters may occur
at the same site as serotonin binding, as these agents have
a similar structure to the neurotransmitter in question.[15]
These inhibitors have a selective effect on the serotonin
reuptake pump, so that an initial increase in serotonin occurs
only at the cell body and the dendrites, not at axon termi-
nals.[2] Consequently, the rate of firing of serotonergic neu-
rones is inhibited and serotonin is released by an action at
5-HT1A somatodendritic autoreceptors.
Longer-term exposure to serotonin eventually causes
downregulation of these 5-HT1A autoreceptors and disinhi-
bition of serotonin release at axon terminals.[16] The delay
in producing the increase in serotonin at the terminals is
usually taken as the reason for the delayed onset of action
of such agents. The increased release of serotinin at the ter-
minals, in the presence of an inhibited serotonin reuptake
pump, increases the availability of serotonin to postsynaptic
serotonin receptors. Such receptors may eventually down-
regulate, but this is a very complex process. Some models
have shown that when extracellular serotonin goes up, its
synthesis and release from vesicles will be inhibited. On
the other hand, when extracellular serotonin goes down, its
synthesis and release from the vesicles will be facilitated.[17]
These complex processes occur because serotonergic
systems must respond rapidly to signals, while ensuring
homeostasis.
A ‘short’ repeat length genetic variation in the promoter
region or exon of the gene that codes for this transporter
has been shown to affect the rate of serotonin uptake and
may play a role in sudden infant death syndrome, aggressive
behaviour in Alzheimer disease patients, post-traumatic
stress disorder and depression susceptibility in people experi-
encing emotional trauma.[18] Recent structural discoveries
regarding the transporter, together with the location, type of
organism inwhich theywere found and a reference, are found
in Table 2.
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INI
VNI
VSV
VGI
VGV
Signalling
efficacy
A A U U U U UUA A AA AG GC C C C
I
V
M S
VG
D
IN
A E C DB
(a)
(b)
(c)
Extracellullar
Intracellular
Figure 1 Serotonin 2c isoforms (reproduced with permission[11]). (a) Proposed 7TM domain structure and amino acid sequence of the serotonin 2c
receptor amino acids subject to aleration by editing shown in coloured spheres. (b) Schematic representation summarising the relationship between
editing and signalling efficacy of respective receptor isoforms. (c) Pre-mRNA sequence of edited region showing editing sites and assigned names des-
ignated for each site. Single-letter codes for amino acids encoded by non-edited transcript shown in black; amino acids encoded after editing at each
position are indicated in blue.
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Genetic variation
The gene that encodes the serotonin transporter is called
Solute Carrier Family 6 neurotransmitter transporter, seroto-
nin, member 4 (SLC6A4). The solute carrier (SLC) group of
membrane transport proteins includes over 300 members
organised into 47 families.[31] Solutes that are transported by
the various solute carrier group members are extraordinarily
diverse and include both charged and uncharged organic
molecules as well as inorganic ions. Depending on the solute
carrier, these transporters are functional as either monomers
or obligate homo- or hetero-oligomers. By convention of
the nomenclature system classifying them, members within
an individual solute carrier family have greater than 20%
sequence homology to each other.[16]
In humans, this gene is found on chromosome 17 on loca-
tion 17q11.1-q12 and is organised into 14 exons. Mutations
associated with this gene may result in changes in serotonin
transporter function and in factmore the 50 different pheno-
typic changes have been discovered as a result of genetic
variation.[26,32]
I425V on chromosome 17 m is found in unrelated families
with obsessive compulsive disorder and it leads to faulty
transporter function and regulation.[33] The presence of
rs-25531 in the same gene of somepatients with this variation
suggests a genetic ‘double hit’, resulting in greater biochemical
effects and more severe symptoms. A variable number of
tandem repeat mutations may occur in the second intron
(STin2). This variation is found with allele repeat numbers 9,
10 and 12. The 12 repeat allele of the STin2 VNTR poly-
morphism has a statistically significant association with
autism.[20] The promoter region of the SLC6A4 gene may
contain a polymorphism with ‘short’ and ‘long’ repeats in a
region. This region is termed the serotonin transporter-
linked polymorphic region or 5-HTTLPR.[34] The short varia-
tion leads to decreased transcription of the gene and may
partly account for anxiety-related personality traits. At least
14 allelic variants of the serotonin transporter-linked poly-
morphic region are known. The low-expression variant of
this type of polymorphism, i.e. the short version, leads to an
increased risk of major depression.
In addition to the alteration of the expression of serotonin
transporter protein and concentrations of extracellular sero-
tonin in the brain, the variation in serotonin transporter-
linked polymorphic region is associated with changes in
brain structure.[35] Enlargement of the thalamus and reduced
cortical volume provide an anatomical basis for explaining
why subjects who inherit such a short–short genotype are
more vulnerable to major depression and suicide.
The short ‘S’ allele of the serotonin transporter gene-linked
polymorphic region has been associated with poorer anti-
depressant response in major depressive disorder and with
antidepressant-induced mania. In about 80% of subjects
homozygous for the ‘S’ allele, fluoxetine treatment develops
new or worsening insomnia (P < 0.005).[36] Also, in around
70% of subjects homozygous for the ‘S’ allele, fluoxetine
treatment develops agitation (P < 0.001). Therefore, the ‘S’
allele of the serotonin transporter gene-linked polymorphic
region may identify patients at risk of developing insomnia
or agitation following fluoxetine treatment.The short variant
allele restricts transcriptional activity of the serotonin trans-
porter promoter, leading to low functional expression of
the serotonin transporter.
Binding of selective serotonin
reuptake inhibitors
SSRIs appear to bind to the serotonin transporterwith similar
rates of occupancy but different duration and potency. The
rate of occupancy of the serotonin transporter exceeds 80%
for sertraline, paroxetine and fluoxetine at minimum thera-
peutic doses.[37] However, the duration of occupancy of the
transporter is significantly shorter for sertraline and paroxet-
ine, which is approximately 10 h less than for fluoxetine,
which is approximately 50 h. The rate of occupancy and the
duration of occupancy tend to indicate a longer-term influ-
ence of fluoxetine on the serotonin transporter.
The most potent reuptake inhibitor in humans is paro-
xetine, followed by clomipramine, a noradrenaline reuptake
inhibitor, citalopram, fluoxetine and imipramine, another
noradrenaline reuptake inhibitor, with no differences
betweenmale and female subjects.All agents, except paroxet-
ine and clomipramine, show significantly lower binding
affinities in elderly subjects of both sexes. It seems that
although the pharmacological profile of the serotonin trans-
porter is not modified qualitatively by age, quantitative
changes in its affinity do perhaps occur. Recent evidence sug-
gests that at tolerable doses SSRIs have increasing occupancy
with increasing plasma concentration.[38]
Table 2 Recent discoveries in serotonin transporter structure
Discovery Position and type Reference
Alpha helices Residues 386–421, rat [10]
Downregulation Whole structure, human [19]
Extracellular loop 4 Residues 386–423, rat [10]
G56A mutation Exon 2, human [20]
‘Hinge’ structure Residues 402–405, rat [10]
Inward current Whole structure, xenopus [21]
I425V mutation Exon 9, human [22]
Length variation mutation 5-HTTLPR, human [23]
Oligomeric structure Whole structure, human [24]
Rs-25531 mutation 5-HTTLPR, human [25]
Rs-25532 mutation 5-HTTLPR, human [26]
SCAMP2 regulation Subcellular, human [27]
SNARE regulation Subcellular, human [28]
Tandem repeats Intron 2, human [29]
Tight regulation Whole structure, human [30]
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The relationship between in vivo brain serotonin trans-
porter binding, plasma concentration and the pharmacologi-
cal effect of SSRIs in mice is of particular clinical interest.[39]
Oral administration of fluvoxamine, fluoxetine, paroxetine
and sertraline at pharmacologically relevant doses exerts a
dose- and time-dependent binding activity of brain serotonin
transporter and the in vivo serotonin transporter-binding
potency is stronger for paroxetine than for fluoxetine and
stronger for sertraline than for fluvoxamine.
The time courses of brain serotonin transporter binding
by SSRIs in mice are mostly in parallel to those of their
plasma concentrations.[40] Also, norfluoxetine has been
suggested to contribute largely to the long-lasting binding
activity of brain serotonin transporter following fluoxetine
administration. Oral administration of SSRIs significantly
suppress a ‘marble-burying behaviour’ in mice, with no
change in locomotor activity and the extent and time course
of suppression agree well with that of brain serotonin
transporter binding.
Updates on transporter function
The plasma membrane serotonin transporter is the major
protagonist in regulating extracellular serotonin concentra-
tion and constitutes the target of drugs used to treat a host of
metabolic and psychiatric disorders. The exact mechanisms
sustaining SERT function still remains elusive. It appears
that external 5-HT reduces both serotonin transport and
serotonin transporter antidepressant binding. In this regard,
5-HT2B receptors are thought to be key players in controlling
the overall serotonin transport system.[41]
In the absence of external 5-HT, 5-HT2B receptor coupling
to nitrous oxide production ensures serotonin transporter
phosphorylation to basal level and maximal serotonin
uptake. In the presence of 5-HT, 5-HT2B receptor-protein
kinase C coupling promotes additional phosphorylations of
both serotonin transporter and Na+, K+-ATPase a-subunit,
impairing the electrochemical gradient necessary for seroto-
nin uptake. Serotonin transporter hyperphosphorylation
also affects antidepressant recognition. Finally, such 5-HT2B
receptor-mediated control of serotonin transporter activity
operates in primary neurones from raphe nuclei.[42]
The serotonin transporter plays a critical role in the main-
tenance of normal neurotransmission by serotonin. Recent
evidence suggests that serotonin transporter and other
neurotransmitter transporters are tightly regulated.[43] Acti-
vation of protein kinase C results in a decrease in serotonin
transporter-mediated 5-HT uptake, which is due to an inter-
nalisation of the transporter. However, little is known about
the mechanism and proteins involved in the downregulation
of the transporter.
One candidate serotonin transporter-regulatory protein
is the SNARE, i.e. soluble N-ethylmaleimide-sensitive
factor-attachment protein receptor, syntaxin 1A (Syn1A),
which has recently been implicated in the regulation of ion
channels as well as the serotonin transporter-related gamma-
aminobutyric acid and glycine transporters. Syntaxin 1A
appears to interact with the serotonin transporter and alters
the subcellular localisation of the transporter, resulting in a
reduction of serotonin transport. The secretory carriermem-
brane protein 2 (SCAMP2) has also been found to play a role
in the regulation of subcellular distribution of serotonin
transporter.[44]
Residues 386–423 of the rat brain serotonin trans-
porter are thought to form a hydrophilic loop connecting
transmembrane regions 7 and 8, known as extracellular
loop 4 (EL4). This extracellular loop has been hypothe-
sised to play a role in conformational changes associated
with substrate translocation.[10] Extracellular loop 4 vari-
ants, such as M386C, appear to show very low transport
activities and low cell surface expression, indicating high
structural and functional importance. It seems that in some
variants, certain amino acid residues in this extracellular
loop are situated in positions highly exposed to the aqueous
environment.
However, in other variants, other amino acid residues
are situated in positions that are either buried in the extra-
cellular loop or functionally unimportant. Positions 386–
399 and 409–421 of the rat brain serotonin transporter
are proposed to form a-helices, connected by amino acid
residues, within which four positions, 402–405, may form
a turn or hinge. The presence of serotonin alters the acces-
sibility of the loop to high affinity reagents. Serotonin-
induced accessibility changes require both sodium ions and
chloride ions since these are associated with active substrate
translocation. Evidence supports the role of extracellular
loops in conformational changes within the serotonin
transporter.[45]
In major depression, in humans and in animal models
of depression, the defect in serotonergic neurotransmission
may originate presynaptically.[46] Such a pathologic state
may be caused by excessive presynaptic autoreceptor activity
in serotonergic neurones and because antidepressants
downregulate the number of these inhibitory receptors,
allowing more normal serotonin release to occur. In fact,
it appears that fluoxetine reduces serotonin transporter
mRNA briefly, but this influence is sustained after several
days of treatment. However, fluoxetine reduces dorsal raphe
5-HT1B mRNA levels in a time-dependent and washout-
reversible manner.[47]
Such a reduction in 5-HT1B mRNA is specific to the dorsal
raphe nucleus and is not found in several postsynaptic,
non-serotonergic regions.[47] Thus, chronic fluoxetine may
be involved in elevating serotonin release from axonal termi-
nals by downregulating mRNA coding for presynaptic
5-HT1B autoreceptors while causing only transient effects on
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serotonin transporter mRNA. Evidence suggests that the
human serotonin transporter has two binding sites, an
orthosteric high-affinity site and a low-affinity allosteric
site.[13] Activation of the allosteric site may increase the disso-
ciation half-life for serotonin.
The reuptake of the neurotransmitters serotonin and nora-
drenaline out of the synaptic cleft is mediated by selective
transporter proteins, the serotonin transporter and the
noradrenaline transporter, respectively. Both transporters
are integral membrane proteins that have a high degree of
homology and represent members of a larger neurotrans-
mitter transporter superfamily. The serotonin transporter
appears to have an oligomeric structure. Also, it has been
shown that serotonin–noradrenaline transporter fusion
proteins are fully active and exhibit the pharmacological
profile of both their individual components.[24] Such findings
support the hypothesis that monoamine transporters are
expressed andmay function as oligomeric proteins composed
of non-interacting monomers.
The downregulation of serotonin transporter is observed
after chronic treatment with selective norepinephrine
reuptake inhibitors (NRIs), such as desipramine but not
following treatment with SSRIs. It appears that both the
binding sites for serotonin and norepinephrine uptake are
decreased in hippocampus and cortex after treatment with
desipramine.[19] In contrast to this, no alteration in the
binding sites for serotonin or norepinephrine uptake is
observed by SSRIs. Also, norepinephrine transporter (NRT)
messenger RNA levels in the locus coeruleus are unchanged
by desipramine treatment. Hence, the marked decrease
in norepinephrine transporter density is caused solely by a
selective NRI.
As shown in the above review, a number of discoveries have
been done in the last few years regarding the structure of the
serotonin transporter. The main structural discoveries,
together with the position in which they are found within the
transporter gene/protein, type of organism producing them
and a reference, are found in Table 2. Furthermore, pH affects
other conducting states of the rat serotonin transporter.
Acidic pH potentiates the serotonin-induced, transport-
associated current and inhibits the hyperpolarisation-
activated transient current. The dose–response relationships
for these two effects suggest that two hydrogen-ion binding
sites, with pKa values close to 5.1 and close to 6.3, govern the
potentiation of the serotonin-induced current and the inhibi-
tion of the transient current, respectively. Such a structure–
function model may explain the permeation properties of
neurotransmitter transporters.[48]
Conclusion
The main action of fluoxetine in the body is its interaction
with the serotonin transporter. The transporter protein
found in the plasma membrane of serotonergic neurones is
responsible for the reuptake of serotonin. SSRIs act primarily
at the serotonin transporter protein and have limited, if any,
reaction with other neurotransmitter systems. The gene that
encodes the serotonin transporter is called Solute Carrier
Family 6 neurotransmitter transporter, serotonin, Member 4
(SLC6A4). Mutations associated with this gene may result in
changes in serotonin transporter function. In fact, more than
50 different phenotypic changes have been identified to be a
result of genetic variation.
SSRIs appear to bind to the serotonin transporter with dif-
ferent rates of occupancy, duration and potency. Research
suggests that external 5-HT reduces both serotonin transport
and serotonin transporter antidepressant binding. Recent
evidence suggests that serotonin transporter and other neu-
rotransmitter transporters are tightly regulated. In major
depression, in humans and in animal models of depression,
the defect in serotonergic neurotransmission may originate
presynaptically. Finally, the human serotonin transporter
has two binding sites, an orthosteric high-affinity site and a
low-affinity allosteric site.Activation of the allosteric sitemay
increase the dissociation half-life for serotonin.
Despite the benefits SSRIs have brought to patients
over therapy which had been previously available, not all
patients benefit from treatment. A better understanding
of the pharmacogenetic mechanisms which may occur due
to gene variants within the serotonin transporter and cyto-
chrome P450 drug-metabolising enzymes may be relevant,
yet studies to date have been very limited, with mixed
results.[5,49,50]
The above review highlights the powerful influence of
serotonin on body processes through its interaction with
ligand-gated and G-protein coupled receptors around the
body and through its uptake from synaptic clefts by the sero-
tonin transporter. Consequently, the activities of both this
neurotransmitter and of the structures it influences are often
the target of research and development sections within large
pharmaceutical industries in order to identify ‘safe’ lead
chemicals that eithermimic or suppress the actions of seroto-
nin so that hopefully, one day, new pharmacological agents
capable of treating resistant forms of somatic and psychiatric
disorders can be licensed for use on an international scale.
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